Hypertensive disorders of pregnancy

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 33, Issue 2, 2004, Pages 209-220

  Peters, Rosalind M ^a   Flack, John M ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Eclampsia; Gestational hypertension; Preeclampsia; Pregnancy induced hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NIFEDIPINE; PHENYTOIN; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DELIVERY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG EXCRETION; DRUG MECHANISM; EMBRYOTOXICITY; FEMALE; HIGH RISK PREGNANCY; HOME CARE; HOSPITAL CARE; HUMAN; HYPOTENSION; LACTATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; MATERNAL MORTALITY; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; OUTPATIENT CARE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; PREECLAMPSIA; RECURRENT DISEASE; SEIZURE; SODIUM RESTRICTION; STANDARDIZATION; ADULT; BLOOD PRESSURE MONITORING; FETOMATERNAL TRANSFUSION; HYPERTENSION; INFANT MORTALITY; NEWBORN; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR; UNITED STATES;

ADULT; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; INFANT MORTALITY; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NURSE'S ROLE; NURSING ASSESSMENT; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; UNITED STATES;

EID: 2342631843     PISSN: 08842175     EISSN: None     Source Type: Journal    
DOI: 10.1177/0884217504262970     Document Type: Article

References (62)

1. Aitken, L., & Addison, C. (1996). The cost-effectiveness of ambulatory blood pressure monitoring. Professional Nurse, 12(3), 198-202.
2. American College of Obstetricians and Gynecologists. (1996a). Hypertension in pregnancy (ACOG Technical Bulletin 218). Washington, DC: Author.
3. American College of Obstetricians and Gynecologists. (1996b). Hypertension in pregnancy (ACOG Practice Bulletin No. 219). Washington, DC: Author.
4. American College of Obstetricians and Gynecologists. (2001). Chronic hypertension in pregnancy (ACOG Practice Bulletin No. 29). Washington, DC: Author.
5. Baker, P. N., Davidge, S. T., Barankiewicz, J., & Roberts, J. M. (1996). Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Hypertension, 27, 56-61.
6. Ballegeer, V. C., Spitz, B., De Baene, L. A., Van Assche, A. F., Hidajat, M., & Criel, A. M. (1992). Platelet activation and vascular damage in gestational hypertension. American Journal of Obstetrics and Gynecology, 166, 629-633.
7. Barron, W. M., & Lindheimer, M. D. (1995). Management of hypertension during pregnancy. In J. H. Largh & B. M. Brenner (Eds.), Hypertension: Pathophysiology, diagnosis, and management (2nd ed., pp. 2427-2450). New York: Raven Press.
8. Barton, J. R., Olson, M. L., & Sibai, B. M. (1994). Monitored outpatient management of mild preeclampsia remote from term. American Journal of Obstetrics and Gynecology, 170, 765-769.
9. Baylis, C., Beinder, E., Suto, T., & August, P. (1998). Recent insights into the roles of nitric oxide and rennin-angiotensin in the pathophysiology of preeclamptic pregnancy. Seminars in Nephrology, 18, 208-230.
10. Blank, S. G., Helseth, G., Pickering, T. G., West, J. E., & August, P. (1994). How should diastolic blood pressure be defined during pregnancy? Hypertension, 24, 234-240.
11. Brown, M. A. (1990). Non-pharmacological management of pregnancy-induced hypertension. Journal of Hypertension, 8, 295-301.
12. Brown, M. A., Buddle, M. L., Farrell, T., Davis, G., & Jones, M. (1998). Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. Lancet, 351, 777-781.
13. Brown, M. A., & Whitworth, J. A. (1999). Management of hypertension in pregnancy. Clinical and Experimental Hypertension, 21, 907-916.
14. Butters, L., Kennedy, S., & Rubin, P. C. (1990). Atenolol in essential hypertension during pregnancy. British Medical Journal, 301, 587-589.
15. Caritis, S., Sibai, B., Hauth, J., Lindheimer, M. D., Klebanoff, M., Thom, E., et al. (1998). Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. New England Journal of Medicine, 338, 701-705.
16. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. I., et al. (2003). The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. Journal of the American Medical Association, 289(1), 2560-2572.
17. Cockburn, J., Moar, V. A., Ounsted, M., & Redman, C. W. (1982). Final report of study on hypertension during pregnancy: The effects of specific treatment on the growth and development of children. Lancet, 1, 647-649.
18. Coetzee, E. J., Dommisse, J., & Anthony, J. (1998). A randomised controlled trial of intravenous magnesium sulfate versus placebo in the management of women with severe preeclampsia. British Journal of Obstetrics and Gynaecology, 105, 300-303.
19. Collaborative Eclampsia Group. (1995). Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet, 345, 1455-1462.
20. Collins, R., Yusuf, S., & Peto, R. (1985). Overview of randomised trials of diuretics in pregnancy. British Medical Journal (Clinical Research Edition), 290, 17-23.
21. Conrad, K. P., & Benyo, D. F. (1997). Placental cytokines and pathogenesis of pre-eclampsia. American Journal of Reproductive Immunology, 37, 240-249.
22. Crowther, C. A., Bouwmeester, A. M., & Ashurst, H. M. (1992). Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? British Journal of Obstetrics and Gynaecology, 99, 13-17.
23. Dekker, G. A., & Sibai, B. M. (2001). Primary, secondary, and tertiary prevention of preeclampsia. Lancet, 357, 209-215.
24. Fischbach, F. (2000). A manual of laboratory & diagnostic tests (6th ed.). Philadelphia: Lippincott.
25. Flack, J. M., Peters, R., Mehra, V., & Nassar, S. (2002). Hypertension in special populations. Cardiology Clinics, 20, 303-319.
26. Gruppo di Studio Ipertensione in Gravidanza. (1998). Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. British Journal of Obstetrics and Gynaecology, 105, 718-722.
27. Hanssens, M., Keirse, M. J., Vankelecom, F., & Van Assche, F. A. (1991). Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstetrics and Gynecology, 78, 128-135.
28. Ito, M., Nakamura, T., Yoshimura, T., Koyama, H., & Okamura, H. (1992). The blood pressure response to infusions of angiotensin II during normal pregnancy: Relation to plasma angiotensin II concentration, serum progesterone level, and mean platelet volume. American Journal of Obstetrics and Gynecology, 166(4), 1249-1253.
29. Johenning, A. R., & Barron, W. M. (1992). Indirect blood pressure measurement in pregnancy: Kortokoff phase 4 vs phase 5. American Journal of Obstetrics and Gynecology, 167, 573-580.
30. Kaplan, N. M. (1998). Clinical hypertension (7th ed.). Baltimore: Williams & Wilkins.
31. Knight, M., Duley, L., Henderson-Smart, D. J., & King, J. F. (2001). Antiplatelet drugs for prevention of pre-eclampsia and its consequences: Systematic review. British Medical Journal, 322(7282), 329-333.
32. Kyle, P. M., & Redman, C. W. (1992). Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy. Drug Safety, 7, 223-234.
33. Levine, R. J., Hauth, J. C., Curet, L. B., Sibai, B. M., Catalano, P. M., Morris, C. D., et al. (1997). Trial of calcium to prevent preeclampsia. New England Journal of Medicine, 337, 69-76.
34. Lindheimer, M. D., & Akbari, A. (2000). Hypertension in pregnant women. In S. Oparil & M. A. Weber (Eds.), Hypertension: A companion to Brenner and Rector's The Kidney (pp. 688-701). Philadelphia: W. B. Saunders.
35. Lockwood, C. J., & Paidas, M. J. (2000). Preeclampsia and hypertensive disorders. In W. R. Cohen (Ed.), Cherry and Merkatz's complications of pregnancy (5th ed., pp. 207-231). Philadelphia: Lippincott, Williams & Wilkins.
36. Lucas, M. J., Leveno, K. J., & Cunningham, F. G. (1995). A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. New England Journal of Medicine, 333, 201-205.
37. Magee, L. A., Ornstein, M. P., & von Dadelszen, P. (1999). Fort-nightly review: Management of hypertension in pregnancy. British Medical Journal, 318, 1332-1336.
38. Magee, L. A., Schick, B., Donnenfeld, A. E., Sage, S. R., Conover, B., Cook, L., et al. (1996). The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. American Journal of Obstetrics and Gynecology, 174, 823-828.
39. Masse, J., Forest, J., Moutquin, J., Marcous, S., Brideau, N., & Belanger, M. A. (1993). Prospective study of several potential biologic markers for early prediction of the development of preeclampsia. American Journal of Obstetrics and Gynecology, 169, 501-508.
40. Mills, J. L., DerSimonian, R., Raymond, E., Morrow, J. D., Roberts, L. J., II, Clemens, J. D., et al. (1999). Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: A multicenter prospective study. Journal of the American Medical Association, 282, 356-362.
41. Minakami, H., Oka, N., Sato, T., Tamada, T., Yasuda, Y., & Hirota, N. (1998). Preeclampsia: A microvesicular fat disease of the liver? American Journal of Obstetrics and Gynecology, 159, 1043-1047.
42. Montan, S., Anandakumar, C., Arulkumaran, S., Ingemarsson, I., & Ratnam, S. S. (1993). Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. American Journal of Obstetrics and Gynecology, 168, 152-156.
43. Myers, M. G. (1999). Ambulatory blood pressure monitoring: A proposal for new Canadian guidelines. Canadian Journal of Cardiology, 15(Suppl. C), 7C-12C.
44. National High Blood Pressure Education Program Working Group. (2000). Working group report on high blood pressure in pregnancy (NHBPEP Publication No. 00-3029). Washington, DC: National Heart Lung and Blood Institute.
45. National Institutes of Health (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). (1997). The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (NIH Publication No. 98-4080). Washington, DC: Author.
46. Penny, J. A., Halligan, A. W., Shennan, A. H., Lambert, P. C., Jones, D. R., de Swiet, M., et al. (1998). Automated, ambulatory, or conventional blood pressure measurement in pregnancy: Which is the better predictor of severe hypertension? American Journal of Obstetrics and Gynecology, 178, 521-526.
47. Piper, J. M., Ray, W. A., & Rosa, F. W. (1992). Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstetrics and Gynecology, 80, 429-432.
48. Plouin, P. F., Breat, G., Llado, J., Dalle, M., Keller, M. E., Goujon, H., et al. (1990). A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy induced hypertension. British Journal of Obstetrics and Gynaecology, 97, 134-141.
49. Poppas, A., Shroff, S. G., Korcarz, C. E., Hibbard, J. U., Berger, D. S., Lindheimer, M. D., et al. (1997). Serial assessment of the cardiovascular system in normal pregnancy. Circulation, 95, 2407-2415.
50. Poston, L. (1996). Maternal vascular function in pregnancy. Journal of Human Hypertension, 10, 391-394.
51. Rey, E., & Couturier, A. (1994). The prognosis of pregnancy in women with chronic hypertension. American Journal of Obstetrics and Gynecology, 171, 410-416.
52. Roberts, J. M., Pearson, G., Cutler, J., & Lindheimer, M. (2003). Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertension, 41, 437-445.
53. Sibai, B. M. (1996). Treatment of hypertension in pregnant women. New England Journal of Medicine, 335, 257-265.
54. Sibai, B. M., Lindheimer, M. D., Hauth, J., Caritis, S., Vandorsten, P., Klebanoff, M., et al. (1998). Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. New England Journal of Medicine, 339, 667-671.
55. Sibai, B. M., Mabie, W. C., Shamsa, F., Villar, M. A., & Anderson, G. D. (1990). A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. American Journal of Obstetrics and Gynecology, 162, 960-967.
56. Sladek, S. M., Magness, R. R., & Conrad, K. P. (1997). Nitric oxide and pregnancy. American Journal of Physiology, 272, R441-R463.
57. Sturgiss, S. N., Wilkinson, R., & Davison, J. M. (1996). Renal reserve during human pregnancy. American Journal of Physiology, 271(1, Pt. 2), F16-F20.
58. Tuffnell, D. J., Lilford, R. J., Buchan, P. C., Prendiville, V. M., Tuffnell, A. J., Holgate, M. P., et al. (1992). Randomised controlled trial of day care for hypertension in pregnancy. Lancet, 339, 224-227.
59. van Oppen, A. C., Stigter, R. H., & Bruinse, H. W. (1996). Cardiac output in pregnancy: A critical review. Obstetrics and Gynecology, 87, 310-318.
60. Visser, W., & Wallenburg, H. C. (1991). Central hemodynamic observations in untreated preeclamptic patients. Hypertension, 17, 1072-1077.
61. von Dadelszen, P., Ornstein, M. P., Bull, S. B., Logan, A. G., Koren, G., & Magee, O. A. (2000). Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet, 355(9198), 87-92.
62. Witlin, A. G., & Sibai, B. M. (1997). Hypertension in pregnancy: Current concepts of preeclampsia. Annual Review of Medicine, 48, 115-127.